erus BioSciences(CHRS) - 2023 Q1 - Quarterly Report

Table of Contents Revenue Cost of Goods Sold Research and Development Expense The decrease in research and development expense was primarily due to: ● a decrease of $1.0 million related to the development of additional presentations of UDENYCA. Three Months Ended March 31, (in thousands) 2023 2022 Change Selling, general and administrative$49,153 $48,753$ 400 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------|-------|-------|-----------|--------|-------|-------|--------| | | | | | | | ...